In this compelling episode of The Life of Flow Podcast, host Miguel is joined by Shon Chakrabarti MD MPH, CMO of Limflow, Michael Siah, Director of Limb Salvage at UT Southwestern Medical Center, and Lucas. Together, they explore the groundbreaking acquisition of Limflow by Inari and its potential to revolutionize the treatment landscape for CLTI patients. Through dynamic discussion and candid reflections, the group unpacks the clinical, technical, and business implications of this strategic merger, highlighting its impact on patient outcomes, institutional approaches, and the future of endovascular therapies.Key Topics Covered:

1. Understanding the Inari-Limflow Synergy (00:01 - 09:52):

• Why the acquisition makes sense for unmet patient needs.
• Strategic alignment with Inari’s ethos of purpose-built solutions.
• Overlaps in vascular innovations and CLTI management.

1. Clinical and Economic Implications of CLTI Therapies (09:53 - 24:04):

• The importance of vertical integration in hospitals for CLTI programs.
• Addressing misconceptions about the costs and outcomes of amputations.
• New reimbursement codes and economic incentives for hospitals.

1. Evolution of DBA Techniques (24:05 - 38:43):

• The journey of deep vein arterialization from experimental to commercial viability.
• Insights into procedural advancements, including new access points and technologies.
• The collaborative WhatsApp group fostering a global exchange of ideas.

1. The Path Forward: Research, Collaboration, and Education (38:44 - 48:24):

• The role of continued peer-to-peer training and global education in scaling CLTI solutions.
• Investigator-Initiated Research Programs to address pressing clinical questions.
• Future product developments and their potential to expand patient reach.

1. What Lies Ahead for CLTI Therapies (48:25 - End):

• Predicting the evolution of the field over the next 5-10 years.
• Controversial yet thought-provoking ideas about preemptive applications of DBA.
• Reflections on patient outcomes and the transformative impact of new therapies.

Memorable Quotes:

• “Inari and Limflow are united by a commitment to tackling large unmet patient needs with purpose-built solutions.” – Shon Chakrabarti
• “Even when DBA patency declines, patients often end up better off than when they started—this is a game changer.” – Miguel

Connect with Us:

• Miguel – https://www.linkedin.com/in/miguel-montero-baker-a44354214/
• Lucas – https://www.linkedin.com/in/lucasferrermd

Guests:

• Shon Chakrabarti – https://www.linkedin.com/in/shon-chakrabarti-md-mph-018a7394/
• Michael Siah – https://www.linkedin.com/in/michael-siah-965585b1/

Stay tuned for future episodes diving deeper into groundbreaking innovations in cardiovascular and endovascular medicine. Don’t forget to subscribe, leave a review, and share this episode with colleagues passionate about transforming patient care!